Connect Enterprise Value over EBITDA from 2010 to 2024
| CNTB Stock | USD 1.39 0.04 2.96% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 0.26 | Current Value 0.27 | Quarterly Volatility 19.09876605 |
Check Connect Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Connect main balance sheet or income statement drivers, such as Interest Expense of 21.9 K, Other Operating Expenses of 948.1 M or Tax Provision of 114 K, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 0.0048. Connect financial statements analysis is a perfect complement when working with Connect Biopharma Valuation or Volatility modules.
Connect | Enterprise Value over EBITDA |
About Connect Biopharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Connect Biopharma income statement, its balance sheet, and the statement of cash flows. Connect Biopharma investors use historical funamental indicators, such as Connect Biopharma's Enterprise Value over EBITDA, to determine how well the company is positioned to perform in the future. Although Connect Biopharma investors may use each financial statement separately, they are all related. The changes in Connect Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Connect Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Connect Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Connect Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. Connect Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 108 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Connect Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Connect Biopharma's short interest history, or implied volatility extrapolated from Connect Biopharma options trading.
Check out the analysis of Connect Biopharma Correlation against competitors. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (0.27) | Return On Equity (0.46) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.